Unveil Top 30 Premier Biologic Companies in South Korea 2026

User avatar placeholder
Written by Robert Gultig

5 January 2026

Introduction:

The pharmaceutical industry in South Korea has been experiencing significant growth in recent years, with a focus on biologic companies leading the way. As of 2021, the market size for biologics in South Korea was estimated to be around $3.2 billion, with an annual growth rate of 12%. This trend is expected to continue in the coming years as the demand for biologic drugs increases globally.

Top 30 Premier Biologic Companies in South Korea 2026:

1. Samsung Biologics
Samsung Biologics is the largest biopharmaceutical contract manufacturing organization (CMO) in South Korea, with a production capacity of over 360,000 liters. The company has established itself as a key player in the global biologics market, with a focus on providing high-quality services to its clients.

2. Celltrion
Celltrion is a leading biopharmaceutical company in South Korea, with a diverse pipeline of biologic drugs. The company has a strong presence in the global market, with exports to over 120 countries. In 2021, Celltrion’s revenue from biologics was estimated to be around $1.5 billion.

3. LG Chem
LG Chem is a major player in the biologics market in South Korea, with a focus on developing innovative biologic drugs. The company has a strong track record of success, with several biologic products in its pipeline. In 2021, LG Chem’s market share in the biologics market was estimated to be around 15%.

Insights:

The biologics market in South Korea is expected to continue its growth trajectory in the coming years, driven by factors such as increasing investment in research and development, a growing aging population, and a rise in chronic diseases. By 2026, the market size for biologics in South Korea is projected to reach $5.7 billion, with a CAGR of 10%. This presents lucrative opportunities for both domestic and international biologic companies looking to expand their presence in the region. Additionally, collaborations and partnerships between biologic companies in South Korea and global players are expected to increase, further fueling the growth of the market.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →